Photo of Joseph F. Quinn, M.D.

Joseph F. Quinn M.D.

    • Professor of Neurology School of Medicine
    • Director OHSU Parkinson Center and Movement Disorders Program School of Medicine
    • Director, Portland VAMC Parkinson’s Disease Research, Education, and Clinical Center (PADRECC)
    • Neuroscience Graduate Program School of Medicine

Director of the OHSU Parkinson Center and Movement Disorder Program

Director of the Portland VAMC Parkinson’s Disease Research, Education, and Clinical Center (PADRECC)

Professor of Neurology, OHSU School of Medicine

Dr. Quinn is NIH and VA-funded to conduct translational research in neurodegenerative disease, including work with animal models, biomarkers, and clinical trials. His research focus is on cognitive decline in Parkinson’s disease and other neurodegenerative diseases.

Read more
  • Residency:

    • Neurology-Oregon Health & Science University, Portland
  • Fellowship:

    • Geriatric neurology-VAMC Portland

Publications

  • "Effects of a γ-secretase inhibitor in a randomized study of patients with Alzheimer disease" Neurology February 2006
  • "Novel antigenic determinant expressed in neurons of the dorsolateral hypothalamus in rat and human" Journal of Neuroscience Research  1992
  • "A combined dataset of human cerebrospinal fluid proteins identified by multi-dimensional chromatography and tandem mass spectrometry" Proteomics February 2007
  • "Vascular dementia" Journal of the American Medical Directors Association November 2003
  • "Nutrient biomarker patterns, cognitive function, and MRI measures of brain aging" Neurology January 24 2012
  • "Age and apolipoprotein E*4 allele effects on cerebrospinal fluid β-amyloid 42 in adults with normal cognition" Archives of Neurology  2006
  • "Influence of lifestyle modifications on age-related free radical injury to brain" JAMA Neurology September 1 2014
  • "Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease" JAMA - Journal of the American Medical Association November 3 2010
  • "Reduced CSF PLTP activity in Alzheimer's disease and other neurologic diseases; PLTP induces ApoE secretion in primary human astrocytes in vitro" Journal of Neuroscience Research May 1 2005
  • "Phytochemicals in Alzheimer disease" Pharmaceutical Biology  2004
  • "Measurement of gelatinase B (MMP-9) in the cerebrospinal fluid of patients with vascular dementia and Alzheimer disease." Stroke  2004
  • "Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression" Annals of Neurology March 2011
  • "Serum vitamin d concentrations are associated with falling and cognitive function in older adults" Journal of Nutrition, Health and Aging October 2012
  • "An aberrant protein complex in CSF as a biomarker of Alzheimer disease" Neurology June 3 2008
  • "Neuroprotective natural antibodies to assemblies of amyloidogenic peptides decrease with normal aging and advancing Alzheimer's disease" Proceedings of the National Academy of Sciences of the United States of America July 21 2009
  • "Targeted discovery and validation of plasma biomarkers of Parkinsons disease" Journal of Proteome Research November 7 2014
  • "CSF multianalyte profile distinguishes Alzheimer and Parkinson diseases" American Journal of Clinical Pathology April 2008
  • "Inflammation and cerebral amyloidosis are disconnected in an animal model of Alzheimer's disease" Journal of Neuroimmunology April 2003
  • "A randomized placebo-controlled pilot trial of omega-3 fatty acids and alpha lipoic acid in Alzheimer's disease" Journal of Alzheimer's Disease  2014
  • "Identification and Validation of Novel Cerebrospinal Fluid Biomarkers for Staging Early Alzheimer's Disease" PLoS One  2011
  • "Nutrient biomarker patterns, cognitive function, and MRI measures of brain aging" Neurology April 17 2012
  • "Safety and acceptability of the research lumbar puncture" Alzheimer Disease and Associated Disorders October 2005
  • "Tau phosphorylation pathway genes and cerebrospinal fluid tau levels in Alzheimer's disease" American Journal of Medical Genetics, Part B: Neuropsychiatric Genetics October 2012
  • "CSF tau/Aβ42 ratio for increased risk of mild cognitive impairment" Neurology August 2007
  • "The ageing systemic milieu negatively regulates neurogenesis and cognitive function" Nature September 1 2011
  • "Amyloid beta peptides in human plasma and tissues and their significance for Alzheimer's disease" Alzheimer's and Dementia January 2009
  • "Cerebrospinal fluid Aβ42, tau, and F2-isoprostane concentrations in patients with Alzheimer disease, other dementias, and in age-matched controls" Archives of Pathology and Laboratory Medicine  2001
  • "Nutritional biomarkers in Alzheimer's disease" Journal of Alzheimer's Disease  2008
  • "Common genetic variants in the CLDN2 and PRSS1-PRSS2 loci alter risk for alcohol-related and sporadic pancreatitis" Nature Genetics December 2012
  • "Alterations in mitochondrial number and function in Alzheimer’s disease fibroblasts" Metabolic Brain Disease April 12 2015

Additional information

Edit profile